Needham analyst Gil Blum reiterated a Hold rating on Fate Therapeutics (NASDAQ: FATE).The analyst commented: "Fate presented updated results for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE